Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study is a research paper published in International Journal of Cancer (2021). On theSindex it has a DataRank of 1.9. It has been cited 62 times, with 56 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.621
From this paper's citation signal
Citation Network Contribution
1.3
From 48 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 56 citers.
GlaxoSmithKline
Grant: NCT01587703
GlaxoSmithKline
Grant: 115521
National Institute for Health Research (NIHR)
Grant: NF-SI-0617-10099
FWCI
3.33
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals